pooled mutant KRAS-targeted long peptide vaccine

A peptide vaccine containing a mixture of long peptides that are derived from tumor-specific mutant forms of the KRAS (K-ras) antigen, with potential immunostimulatory and antitumor activities Upon administration of the pooled mutant KRAS-targeted long peptide vaccine, the KRAS peptides may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against KRAS-expressing tumor cells. KRAS, a tumor-associated antigen (TAA) that plays a key role in the RAS/mitogen-activated protein kinase (MAPK) signaling pathway, is overexpressed on a variety of tumor cell types.